Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Ependymoma 1

Interventions

pembrolizumab 254Cyclophosphamide 244Specimen Handling 196fludarabine 173Magnetic Resonance Spectroscopy 170Biopsy 145Nivolumab 124Carboplatin 99Radiotherapy 92Paclitaxel 90venetoclax 81Cisplatin 80fludarabine phosphate 79Gemcitabine 78Injections 69Ipilimumab 66Dexamethasone 63atezolizumab 58Cetuximab 57Bevacizumab 57Azacitidine 57Radiation 56Fluorouracil 56durvalumab 54Radiosurgery 51Temozolomide 48Oxaliplatin 44Rituximab 43Irinotecan 43Docetaxel 43

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Flow Cytometry × 1 year × Clear all
NCT01795313 2026-02-05

Immunotherapy for Recurrent Ependymomas in Children Using Tumor Antigen Peptides With Imiquimod

University of Pittsburgh

Phase 1 Terminated
23 enrolled

Ependymoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡